CV Therapeutics Lets Innovex Do the Legwork--and Pay for Some of It, Too
Contract Sales Organizations have moved past their rent-a-rep past and are now trying to market themselves as full service marketing outsourcers which provide alternatives to co-marketing and outlicensing.. Innovex's recent deal with CV therapeutics, is a case-in-point and may provide a model for biotechs--and even some pharmaceutical companies--to follow in launching products on their own without incurring huge fixed costs.
You may also be interested in...
The European Medicines Agency commits to exploring real-world data as part of its new Regulatory Science Strategy to 2025.
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.